Biocompounds Pharmaceutical Inc.

Methyldopa API Completes Domestic Registration

2026.09.10

Return Next：

21

2025.09

Anhui Biocompounds C

On September 19, the Quality Department of Anhui Biocompound

On August 25, Anhui Bocompounds Pharmaceutical Co., Ltd received the domestic registration approval notification issued by the National Medical Products Administration (NMPA) for its Methyldopa API.

Methyldopa is the preferred treatment for pregnancy-induced hypertension, with stable clinical demand and good market prospects. Previously, Anhui Bocompounds Pharmaceutical Co., Ltd Methyldopa API had obtained the EU Written Confirmation (WC) export certificate—a "door-opener" to the international market. After completing domestic registration, it has now formally obtained domestic-market access qualification, further enriching Jianfeng Beika's API product pipeline in the cardiovascular field, consolidating the company's API business strength in its pharmaceutical segment, creating favorable conditions for subsequently expanding domestic formulation customers and growing its domestic and overseas market share, and better realizing a two-way domestic-and-international market layout.